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Abstract
Aims—Mesenchymal stem cells (MSCs) are multipotent cells with immunomodulatory 
properties. We tested the ability of MSCs to delay islet allograft rejection.
Methods—Mesenchymal stem cells were generated in vitro from C57BL/6 and BALB/c mice 
bone marrow, and their immunomodulatory properties were tested in vitro. We then tested the 
effect of a local or systemic administration of heterologous and autologous MSCs on graft survival 
in a fully allogeneic model of islet transplantation (BALB/c islets into C57BL/6 mice).
Results—In vitro, autologous, but not heterologous, MSCs abrogated immune cell proliferation 
in response to alloantigens and skewed the immune response toward a Th2 profile. A single dose 
of autologous MSCs co-transplanted under the kidney capsule with allogeneic islets delayed islet 
rejection, reduced graft infiltration, and induced long-term graft function in 30 % of recipients. 
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Based on ex vivo analysis of recipient splenocytes, the use of autologous MSCs did not appear to 
have any systemic effect on the immune response toward graft alloantigens. The systemic injection 
of autologous MSCs or the local injection of heterologous MSCs failed to delay islet graft 
rejection.
Conclusion—Autologous, but not heterologous, MSCs showed multiple immunoregulatory 
properties in vitro and delayed allograft rejection in vivo when co-transplanted with islets; 
however, they failed to prevent rejection when injected systemically. Autologous MSCs thus 
appear to produce a local immunoprivileged site, which promotes graft survival.
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Introduction
The standard treatment for type 1 diabetes (T1D) is exogenous insulin injection, which 
efficiently improves glycometabolic control [1, 2]. However, insulin treatment cannot fully 
prevent the development of the severe chronic complications related to diabetes, such as 
kidney failure, coronary heart disease, retinopathy, and neuropathy [3–7]. Islet 
transplantation is a relatively low-invasive procedure that has been shown to normalize 
glycemia and effectively counteract the development of diabetic complications [8–13]. 
Unfortunately, the recurrence of autoimmunity and the development of alloimmune anti-islet 
response greatly jeopardize the long-term function of the islets, which remains poorer 
compared to that of other grafts (below 20 % at 5 years) [8, 14]. Various immunomodulatory 
strategies have been thus tested or are currently under investigation to prevent auto- [15, 16] 
and alloimmunity [17, 18] and thus promoting islet graft survival [8, 17, 18]. However, the 
potential dangerous side effects of immunosuppression are currently of concerns [19]. Since 
the discovery of mesenchymal stem cells (MSCs) [20], numerous clinical trials based on 
them have been conducted, and a large part of these studies can be attributed to the interest 
on their immunosuppressive properties [21–24]. MSCs, often found and isolated from the 
bone marrow (although not exclusive to this location), are pluripotent cells with the 
capability of differentiating into various cell types such as osteoblasts, chondrocytes, and 
adipocytes [23, 25]. Known for their plasticity, or the ability to be molded into a desired 
form, MSCs have been researched in many fields including diabetes, transplants, cardiology, 
and oncology. More recently, MSCs have also been shown to play a part in 
immunomodulation [26]. In vitro, MSCs inhibit T cell proliferation and promote regulatory 
T cell function and generation [27, 28]. In vivo MSCs have been shown to modulate 
autoimmune response in different murine models of diabetes [23, 29], multiple sclerosis 
[22], rheumatoid arthritis [30], and alloimmune response in models of islet and heart 
transplantation [31, 32]. In particular, MSCs have been shown to modulate anti-allogeneic 
islet response in an immunodeficient mouse after CD4+ T cell reconstitution [32]. In our 
study, we evaluated the potential of bone-marrow-derived MSCs to modulate anti-islet 
response in immunocompetent mice; in particular, we dissected the difference in graft 
protection obtained by the use of autologous or heterologous MSCs and by their 
administration (either systemically or locally at the graft site). We believe that the data 
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C57BL/6 and BALB/c mice were purchased from the Jackson Laboratory at Bar Harbor, 
Maine. All mice were housed under specific pathogen-free conditions at an Association for 
Assessment and Accreditation of Laboratory Animal Care International (AAALAC) 
accredited facility at Boston Children’s Hospital. Institutional guidelines and protocols were 
approved in adherence to the Institutional Animal Care and Use Committee (IACUC).
Murine islet transplantation
Islets were isolated from the pancreas of donor mice (BALB/c) [18] and transplanted under 
the kidney capsule of diabetic C57BL/6 mice induced with streptozotocin [(Sigma-Aldrich, 
St. Louis, MO) 225 mg/kg, administered i.p.]. Islet rejection is characterized by blood 
glucose levels >250 mg/dl for two consecutive days post-transplant [18].
MSC culture
Bone marrow mononuclear cells were isolated from the tibiae and femurs of C57BL/6 mice 
in order to generate MSC. 10 × 106/25 cm2 of MSC was seeded into flasks and was coated 
with M10 medium [DMEM medium (Cambrex) containing 10 % FCS (HyClone), 1 % 
penicillin–streptomycin, and 1 % L-glutamine (both from Cambrex)] [23].
MSC differentiation
MSC passaged at P4 was trypsinized, cultured, and induced with three varying conditions to 
verify pluripotentiality and the ability to differentiate into multiple cell types: osteocytes, 
adipocytes, and chondrocytes. Differentiation of MSCs into appropriate cell types was 
performed as previously described [23].
Interventional studies
5 × 105 recipient-derived MSC was administered through i.v. (systemic) or intragraft (local) 
during BALB/c islet into C57BL/6 kidney transplant (islet tx). After transplantation, mice 
were monitored daily by blood glucose measurement and the return to hyperglycemia was 
considered a sign of graft rejection. Blood glucose was measured using a BD Logic blood 
glucose meter (Becton–Dickinson, Franklin Lakes NJ).
Histology and immunohistochemistry
Kidney tissues were snap frozen embedded in OCT. Immunohistochemistry was performed 
as previously described [33]. Photomicrographs (400× or 200×) were taken using an 
Olympus BX41 microscope (Center Valley, PA). The following primary antibodies were 
used: anti-CD4, anti-CD8 (both from eBioscience, San Diego, CA), and anti-insulin (Dako 
North America, Carpinteria, CA). Immunohistochemistry was performed as well on 
formalin-fixed, paraffin-embedded tissue sections related to the graft. Photomicrographs 
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(original magnification 40×) were taken using an Olympus BX41 microscope (Center 
Valley, PA). The antibodies used were Mouse anti-CD31 (PECAM-1) (Life Technologies, 
Carlsbad, CA, USA). Histology was evaluated by an expert pathologist.
Insulitis score
Insulitis scoring was performed as published [34] on hematoxylin- and eosin-stained graft 
sections (kidneys + islets). (i) Insulin staining: 0: no insulin staining, 1: presence of scattered 
insulin-positive cells, 2: presence of insulin-positive cell aggregates, 3: presence of 
preserved insulin-positive islets; (ii) Islet cell infiltrate: 0: no cell infiltrate, 1: presence of 
cell infiltrate around graft islets, 2: presence of cell infiltrate inside graft islets, 3: presence 
of cell infiltrate throughout the graft area without preserved islet structure.
Quantitative real-time PCR
RNA extracted from cultured MSCs was purified using an RNeasy kit (Qiagen, Valencia, 
CA) and reverse-transcribed into cDNA using Superscript III (Invitrogen, Carlsbad, CA). 
Transcript amplifications were read through a 7300 real-time PCR system. Primers were 
purchased from Applied Biosystems (Foster City, CA) and quantified by normalization of 
cytokines (CX3CR1, Fractalkine, CXCL19, CXCR6, SDF-1α, CXCR4, VEGF, CXCR2, 
IP-10, MIG, ITAC, MIP-10, IL-10, IL-12, IFN-γ, and TGF-β) to copies of GAPDH [35].
ELISPOT
To measure cytokine production by MSCs, an ELISPOT assay, following manufacturer’s 
protocol (BD Biosciences, San Jose, CA), was used to assess IFN-γ-, IL-4-, and IL-5-
producing cells. Spots were counted using an Immunospot analyzer (Cellular Technology 
Ltd., Cleveland, OH) [36].
Flow cytometric analysis and intracellular cytokine staining
Flow cytometry was performed to analyze surface expression markers of MSCs. Anti-mouse 
MHC Class I, CD28, CD90, CD13, and CD34 were purchased from BD Pharmingen and 
eBioscience (San Diego, CA). CD4, CD44, CD62L, CD25, CD105, interferon-γ, IL-17A, 
IL-10, and FoxP3 were purchased from BD Pharmingen and eBioscience (San Diego, CA). 
Cells recovered from spleens and peripheral bloods were subjected to FACS analysis and 
were run on a FACSCalibur™ (Becton–Dickinson). Data were analyzed using FlowJo 
software version 6.3.2 (Treestar, Ashland, OR).
Mixed lymphocyte reaction (MLR)
BALB/c splenocytes were irradiated at 3000 rads and used to stimulate C57BL/6 
splenocytes at a ratio of 1:1. T cell proliferation was measured at day 3 following pulsing for 
3 h with TdR (Perkin Elmer, Wellesley, MA), and cell counts were quantified using a liquid 
scintillation counter.
Statistical analysis
All data are expressed as mean ± standard error of mean. Survival data were analyzed 
through the Kaplan–Meier analysis. A two-sided unpaired Student’s t test (for parametric 
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data), or a Mann–Whitney test (for nonparametric data), was used to compare groups. A p 
value of less than 0.05 (by two-tailed testing) was considered to be statistically significant. 




We first evaluated and characterized MSCs generated from the bone marrows of C57BL/6 
mice. MSCs were passaged at P4 and then characterized through flow cytometry with a wide 
array of antibodies, including: MHC Class I, CD28, Thy-1 (also referred to as CD90), 
CD34, and CD13. The results obtained confirmed the MSCs phenotype of the generated 
cells (Fig. 1a). In order to assess the pluripotency of the generated cells, we evaluated their 
potential of differentiating under specific conditions (Fig. 1b). Color changes in the media 
were indicative of MSCs passages into appropriate cell types: chondrocytes, osteoblasts, or 
adipocytes. Similar to the phenotype data, differentiation assays confirmed that the 
generated cells were indeed MSCs [23].
MSC secretome
We then assessed the secretome profile of MSCs alone through ELISPOT assays; 
particularly, the number of interferon-γ (IFN-γ)-, interleukin-4 (IL-4)-, and interleukin-5 
(IL-5)-producing cells was evaluated. To determine the optimal dosage of C57BL/6 MSCs to 
be injected, we tested four different concentrations of MSCs alone: (1) 10,000 (2) 25,000 (3) 
50,000, and (4) 100,000 (Fig. 1c). Results show a concentration-dependent increase in IL-4 
production (100,000 C57BL/6-MSCs vs. 10,000 C57BL/ 6MSCs; p = 0.0002; Fig. 1d). 
Partial production of IFN-γ was also observed, while only marginal levels of IL-5 were 
detected (Fig. 1d). We then further quantified the cytokine profile of the MSCs through RT-
PCR. RNA was extracted from the MSCs and normalized against GAPDH. Data show that 
the MSCs were positive for SDF-1α and TGF-β (Fig. 1e, f).
MSCs immunomodulatory properties
We then determined in vitro the effect of generated MSCs in modulating the alloimmune 
response. 1 × 106 C57BL/6 responder splenocytes were stimulated with the same number of 
irradiated stimulator BALB/c splenocytes in the presence or absence of 1x105 C57BL/6 
(autologous) or BALB/c (heterologous) MSCs, and in an ELISPOT assay the numbers of 
INF-γ-(Fig. 2a, b) and IL-4-producing cells were tested (Fig. 2c, d). While heterologous 
MSCs had only marginal effect on cytokines production, the use of autologous MSCs 
greatly modified cytokine production profile compared to cells cultured in the absence of 
MSCs (Fig. 2b, d). Specifically higher numbers of IFN-γ- and IL-4-producing cells were 
observed (IFN-γ, number of spots: no MSCs = 14, autologous MSCs = 559; n = 6; p = 
0.0007; Fig. 2b; IL-4 number of spots: no MSCs = 54, autologous MSCs 1528; n = 6; p ≤ 
0.0001; Fig. 2d) with IL-4 produced in a higher quantity (about threefold if compared to 
IFN-γ). The effect of the higher IL-4 production could suggest a shift toward a Th2 profile. 
We then ran an MLR experiment to measure in vitro alloantigen response with different 
dosage of autologous MSCs (n = 3; Fig. 2e). A dose-dependent suppression of BALB/c 
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splenocytes mediated C57BL/6 splenocytes proliferation was observed, and a plateau was 
present with more than 1000 MSCs (Fig. 2e).
MSC co-transplantation prolongs islet allograft survival
We then tested, in vivo, the immunological properties of C57BL/6 (autologous) MSCs in 
promoting allogeneic islet graft survival. BALB/c islets were transplanted under the kidney 
capsule of streptozotocin-induced diabetic C57BL/6 mice. Untreated mice invariably 
rejected transplanted islets in less than 14 days [median survival time (MST) 12 days] (Fig. 
3a); similarly, the systemic i.v. injection of 5 × 105 P4 autologous MSCs was not able to 
prolong islet graft survival (MST 15.5 days; p = ns vs. untreated). We also investigated the 
local immunosuppressive potential of autologous MSCs by infusing them at the site of 
transplantation. Generated P4 MSCs were mixed at the time of the infusion to the purified 
BALB/c-derived islets and then co-transplanted under the kidney capsule of diabetic 
C57BL/6 recipients. In this setting, delay of graft rejection was evident (MST 20 days, n = 
8; p = 0.01 vs. untreated; Fig. 3b) with long-term islet graft survival achieved in about 30 % 
(n = 3) of the islet-transplanted mice (Fig. 3b). Furthermore, in order to determine whether 
BALB/c (heterologous) MSCs would also have a similar local effect, we infused BALB/c-
derived MSCs together with BALB/c islets. The use of heterologous MSCs, however, was 
ineffective in promoting islet graft survival prolongation (Fig. 3c), unlike the results of the 
autologous MSCs.
Locally MSC-treated mice showed preserved islet allograft
Islet grafts from locally infused autologous MSC-treated (n = 3) and untreated recipients (n 
= 3) were harvested at day 14 after transplantation, and immunohistochemistry was 
performed (Fig. 4a–e, f–j). Untreated mice displayed, at the site of transplantation, lack islet 
structures or positive insulin staining, with CD4+ and CD8+ T cells evident throughout the 
graft area (Fig. 4c–d). On the contrary, the graft area of recipients treated with locally 
infused autologous MSCs showed preserved islet structure and clear positive insulin 
staining. CD4+ and CD8+ T cells are present, but mainly localized at the border of the islets 
with minimal infiltration of the graft (Fig. 4h–i). Furthermore, the analysis of insulin 
staining (Fig. 4k) and of the insulitis score or infiltrate score (Fig. 4l) confirmed that islet 
grafts are more preserved and less infiltrated in the MSC-treated group as compared to the 
untreated group. This indicates that co-transplanted MSCs may contribute to the prevention 
of islet infiltration and loss.
Co-transplantation of MSCs promotes revascularization of transplanted islets
To test and evaluate the impact of MSCs on the vascularization of the islets, we assessed 
CD31 staining, a marker of endothelial cells. A more pronounced CD31 staining was evident 
in locally MSC-treated mice (Fig. 4j) as compared to the untreated one (Fig. 4e), suggesting 
a potential role of MSCs in stimulating revascularization.
Locally MSC-treated mice showed reduced alloimmune response
Upon observing that locally or systemically infused autologous MSCs prolong islet graft 
survival, we decided to examine whether this was related to a local immune effect or 
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whether a systemic effect was also present. Recipient splenocytes were extracted at 14 days 
after transplantation in both untreated and systemically or locally autologous MSC-treated 
mice, and proliferation in response to irradiated donor-derived splenocytes was assessed. No 
difference in thymidine incorporation was observed between untreated and systemically 
MSC-treated mice (Fig. 5a). Thymidine incorporation, as a marker of cell proliferation, was 
lower in the locally MSC-treated mice as compared to the systemically MSC-treated ones (p 
<0.001), (Fig. 5a). We then tested in an ELISPOT assays the number of generated recipient 
IFN-γ and IL-4 producing cells in response to irradiated donor-derived splenocytes. Locally 
MSC-treated mice showed a significant reduction in the number of IFN-γ-producing cells as 
compared to systemically MSC-treated mice (p <0.05), (Fig. 5b). On the contrary, we 
observed a significant increase in the number of IL-4 producing cells in the locally MSC-
treated mice as compared to the untreated and systemically MSC-treated mice (p <0.05 and 
p <0.01, respectively) (Fig. 5c). These data suggest that the prolongation of islet allograft 
survival in autologous locally MSC-treated mice may be due to the creation of a local 
immunoprivileged site which prevents allostimulation.
MSC co-transplantation abrogates the Th17 immune response
We next tested the effect MSCs co-transplantation on immunophenotype of recipient mice. 
We harvested splenocytes and peripheral blood from MSC-treated mice (systemically and 
locally) at day 14, and the percentages of CD4+ T effectors cells (CD4+CD44highCD62Llow, 
or CD4+ Teffs), regulatory FoxP3+ T cells (CD4+CD25+ FoxP3+), regulatory IL-10+ T cells 
(CD4+IL-10+), IL-17+ T cells (CD4+IL-17+), and IFN-γ+ T cells (CD4+IFN-γ+) were 
quantified by flow cytometry analysis (Fig. 5d–m). No differences were observed in the 
percentage of CD4+ T effector cells (CD4+CD44highCD62Llow) (Fig. 5d, i) or FoxP3+ T 
cells (Fig. 5h, m) in the spleen and blood of both MSC-treated mice as compared to 
untreated ones. The percentage of IL-17+ T cells, but not of IFN-γ+ T cells, was lower in the 
spleen and blood of locally MSC-treated group as compared to untreated controls and 
systemically treated mice (Fig. 5e–f, j–k). Furthermore, we observed a tenfold increase in 
the percentages of IL-10+ regulatory T cells in the spleen (Fig. 5g), but not in the blood (Fig. 
5l), of locally MSC-treated mice as compared to untreated controls and systemically treated 
mice. This suggests that co-transplantation of MSCs with islets transplantation may reshape 
recipients’ immune system.
Locally co-transplanted MSCs remained within the islet graft
In order to track administered MSCs in mice, GFP+MSCs were injected in islet-transplanted 
mice and GFP/CD105 double staining was performed and quantified (Fig. 6a–l). Flow 
cytometry analysis revealed that MSCs administered locally and systemically traffick to the 
spleen (Fig. 6d–f, **p <0.01) but poorly to the liver (Fig. 6j–l). While in untreated islet-
transplanted mice, WT mice, and Isotype control, GFP/CD105 double-positive cells are 
poorly represented (Fig. 6a–c, g–i).
Discussion
T1D has been associated with a wide range of complications [37, 38], and unfortunately 
while immunotherapy showed some promising results in the murine model of T1D (the 
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NOD mice) [39], the results in humans are poor. Of interest stem cells are now recognized as 
a tool for immunomodulation and regeneration [40]. Islet transplantation has been shown to 
normalize glycemic control and counteract the development of the chronic complications 
associated with T1D [41]. However, in spite of countless research and effort, long-term 
survival of islet grafts remains far below the survival rate of other types of grafts. In our 
study, we took advantage of the immunomodulatory properties of MSCs to promote 
allogeneic islet graft survival in a murine model of allogeneic transplantation. Specifically, 
(1) we generated BALB/c and C57BL/6 bone-marrow-derived MSCs under established 
protocols; (2) we evaluated the profile of MSCs at P4 using RT-PCR and ELISPOT showing 
a potential immunomodulatory profile; (3) we examined the effect of autologous (C57BL/6) 
MSCs on the alloimmune response in vitro, which showed higher immunomodulation 
obtained by responder autologous cells; (4) we tested the effect of autologous MSCs on islet 
graft (BALB/c → C57BL/6), with survival confirming higher effectiveness of autologous 
MSCs; and (5) we compared local and systemic administration of MSCs and demonstrated 
that locally infused MSCs promote better immunomodulation. Although the 
immunoregulatory properties of MSCs have been shown as beneficial in different murine 
models of transplantation, several issues remain to be solved in order to make MSCs a viable 
option for clinical practice.
The first issue is related to the high number of MSCs, often in multiple doses, that are 
needed to generate an in vivo relevant immunological effect [23]. In our study, we 
demonstrated that the use of a relatively low single-dose injection of MSCs is effective, but 
only if the cells are directly infused at the site of transplantation. On the contrary, the same 
dose of MSCs infused systemically loses its effect and is not able to promote graft survival. 
When we tested the immune system of mice either untreated or treated with locally injected 
MSCs, we did not see any difference in terms of alloantigen response. Therefore, we 
propose that the local injection of MSCs does not affect the priming of the immune system 
toward the graft antigens, but that it generates a local immunoprivileged site where islet graft 
is protected from the aggression of the immune system. The results of the histology are 
compatible with this model; in fact, CD4+ and CD8+ T cells appear to infiltrate the graft 
area, but are disposed at the border of single graft islets without the invasion typical of florid 
rejection. The creation of an immunoprivileged site without a systemic immunological effect 
could be desirable in transplantation because it may avoid the potential side effect related to 
systemic immunomodulation (such as reduced protection toward pathogens and reduced 
immunosurveillance toward dysplastic cells).
The second issue is related to the source of MSCs (autologous vs. heterologous). The source 
of MSCs has been debated in recent years, and autologous vs. heterologous MSCs have been 
challenged in different models [32, 42], with either cells resulting as desirable in different 
settings. In general, autologous MSCs are described to have a much better effect at 
prolongation; however, heterologous MSCs are often described as superior in cases such as 
autoimmune disease (in which autologous MSCs might be dysfunctional as well) and so 
would result in a better safety profile [23]. In our setting, we hypothesized that the 
superiority of autologous MSCs could be linked to the rejection of heterologous MSCs due 
to the host immunosurveillance [43–45].
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It is possible that in our study, more than an immunoprivileged local mechanism, the mild 
effect observed with autologous MSC could be just related to a promotion of a 
microenvironment that limits islet damage as indicated by other studies in syngenic models 
[44, 45]. Autologous MSCs may prevent islet cells loss and suppress various immune cell 
functions caused by pro-inflammatory cells and cytokines and facilitate islet 
revascularization and engraftment [44, 45]. This effect could be abrogated in the case of the 
heterologous MSC due to the host immunosurveillance.
The immunomodulatory properties of MSC have been largely described in the literature, and 
several reports have described that they do exert their effects through the release of several 
trophic factors such as CNTF [46], already known to promote islet graft survival and other 
trophic factors such as hepatocyte growth factor, Von Willebrand factor, transforming growth 
factor-β1 [47], prostaglandin E2, or via establishing a cell-to-cell communication network 
[48]. Furthermore, recent published studies [48, 49] suggested that MSCs may also 
communicate through the release of circular membrane fragments named microvesicles 
(MVs) that are able to shuttle proteins and genetic information from cells of origin to target 
cells [49]. Favaro et al. provided a new evidence regarding the immunomodulatory 
mechanism governed by MSC-derived microvesicles, which were found to exert an anti-
inflammatory effect by decreasing pro-inflammatory cells and cytokines, and by triggering 
in the meanwhile an increase in anti-inflammatory-associated cytokines, suggesting the 
switch to an anti-inflammatory response of T cells [48]. MVs may be released from EPCs as 
well and induce a protective effect on human islets via triggering neoangiogenesis, and MVs 
may be internalized by β-cells and islets endothelium sustaining thus insulin secretion and 
angiogenesis [49].
Herein, we showed and confirmed what has been reported by other investigators [44, 45] 
that co-transplantation of MSCs with islets from BALB/c into streptozotocin-treated 
C57BL/6 recipients’ mice would facilitate islet revascularization, engraftment, and improved 
graft survival, and due to its beneficial outcomes on transplantation such procedure 
employing co-transplantation of MCSs with islets may be translated into the clinical 
settings.
Lastly, we also considered the mechanisms underlying the immunomodulatory properties of 
MSCs. In different models, MSCs have been shown to express a wide array of mechanisms 
that have been considered responsible for the immunological effect achieved [50]. These 
mechanisms include the inhibition of T cell activation and proliferation [51], the modulation 
of dentritic cell activation [52], the modulation of NK cells activity [53], and the inhibition 
of B cell activation [54]. In our study, we demonstrated a high IL-4 spontaneous production 
by MSCs, which is able to commit, in an antigen-specific assay, immune cells toward a Th2 
profile. Th2 profile is well established to be associated with a reduced allospecific response 
and graft rejection. The production of TGF-β by MSCs might also contribute to the down-
regulation of anti-islet response and the graft protection observed.
In conclusion, islet transplantation presents the unique opportunity to effectively co-
transplant MSCs [55]; our data demonstrated that MSCs co-transplantation may be 
beneficial when co-injected with islets and may improve islet graft survival, with the 
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generation of an immunoprivileged site that can halt locally anti-islet responses without any 
systemic effect on the recipient immune system.
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Characterization of MSCs. C57BL/6 MSCs were characterized through flow cytometry, 
ELISPOTs, RT-PCR, and MSCs delineation. Flow cytometry was performed to characterize 
the phenotype of C57BL/6 MSCs. Results show that C57BL/6 highly express MHC Class I 
and CD13, but express low amounts of CD28, Thy-1, and CD34 (a). b Shows the 
delineation of MSCs into chondrocytes, osteoblasts, and adipocytes (i.e., color = positive 
effect) when MSCs were cultured accordingly to protocol (b). c and d, MSCs secretome was 
assessed and C57BL/6 MSCs were plated alone, MSCs produced high amount of IL-4 
cytokine at a concentration of 100,000 cells and some percentage of IFN-γ (IFN-γ **p 
<0.01, IL-4 ***p <0.001) (c, d). Lastly, RT-PCR results show that C57BL/6 MSCs are 
positive for SDF-1α and TGF-β (e, f). Data are shown as mean ± SEM and are representative 
of n = 3 mice and of at least two independent experiments. **p <0.01; ***p <0.001
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Immunomodulatory properties of MSCs. 1 × 106 C57BL/6 responder splenocytes were 
stimulated with irradiated stimulator BALB/c splenocytes in the presence or absence of 1 × 
105 autologous-C57BL/6 or heterologous BALB/c MSCs, and in an ELISPOT assay the 
production of INF-γ (a) and IL-4 was tested (c). While heterologous MSCs had only 
marginal effect on cytokines production (b, d), the use of autologous MSCs greatly modified 
cytokine production profile compared to cells cultured in the absence of MSCs (***p 
<0.001; b, d). An MLR experiment shows a dose-dependent reduction of C57BL/6 
splenocytes challenged with irradiated BALB/c splenocytes and autologous MSCs (e). Data 
are shown as mean ± SEM and are representative of at least two independent experiments. 
***p <0.001
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Survival of allogeneic islet transplant with (systemically or locally) or without MSCs. The 
systemic injection of autologous C57BL/6 MSCs is not able to promote allogeneic islet graft 
survival (a), on the contrary the local infusion (into kidney capsule together with islet graft) 
of the same number of MSCs promote graft survival (b) (**p <0.01 vs. untreated). 
Conversely, the local infusion of heterologous BALB/c MSCs has no effect on islet graft 
survival (c). P values were calculated with Student’s t test. Data are representative for at 
least five mice per group. **p <0.01
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Pathology of the graft at day 14 after transplantation. The islet graft of untreated mice 
showed no preserved structures or insulin staining (a, b, k), while in locally MSC-treated 
mice, the islet graft showed preserved structures and positive insulin staining (f, g, k). CD4+ 
and CD8+ T cell infiltrate is evident (l) but mostly confined outside the islets (h–i) in locally 
MSC-treated mice, as compared to untreated mice, which showed overall more infiltrate (c–
d, l). CD31 staining, a marker of endothelium and vascularization, appeared to be more 
evident in islet graft of mice locally MSC-treated mice (j) as compared to samples obtained 
from untreated mice (e). All the generated data are representative of at least n = 3 mice per 
group. *p <0.05; **p <0.01
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Immunophenotype of treated mice. Proliferation toward donor antigens was reduced in the 
locally autologous MSC-treated mice compared to systemically MSC-treated mice (a). We 
found significant difference in terms of cytokine production toward graft antigens between 
untreated, locally and systemically MSC-treated mice, with a reduction in the number of 
IFN-γ-producing, and an increase in IL-4-producing, cells in mice treated with MSCs locally 
(b–c). The percentage of CD4+ effector T cells in the spleen (d) and in the blood (i) is 
unaffected by both treatments with MSCs, and MSC co-transplantation reduces the 
percentage of IL-17+ (e, J) and IFN-γ+ (f, k) cells. While the percentage of FoxP3+ 
regulatory CD4+ T cells is unaltered (h, m), a tenfold increase in the percentage of IL-10+ 
CD4+ T cells was evident in the spleen (g), but not in the blood (l), of mice locally treated 
with MSCs. Scale bars show mean ± SEM for at least n = 3 mice, and data are representative 
of two independent experiments. *p <0.05; **p <0.01; ***p <0.001
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MSCs tracking. In order to track administered MSCs in mice, GFP+MSCs were injected in 
islet-transplanted mice and GFP/CD105 double staining was performed and quantified (a–l). 
Flow cytometry analysis revealed that MSCs administered locally and systemically traffick 
to the spleen (d–f) but poorly to the liver (j–l). In untreated islet transplanted mice, WT 
mice, and Isotype control, GFP/CD105 double-positive cells are poorly represented (a–c, g–
i). Data are shown as mean ± SEM and are representative of n = 3 mice and of at least two 
independent experiments. **p <0.01
Ben Nasr et al. Page 18
Acta Diabetol. Author manuscript; available in PMC 2016 August 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
